These results surpass previous benchmarks set by regorafenib, fruquintinib, and FTD/TPI monotherapy in similar patient populations.4–6,22 A notable reduction in serum IL-6 levels, an IL-1-induced cytokine, was associated with improved therapeutic response, highlighting the on-target activity of XB2001. The gene discussed is IL1B; the disease is frontotemporal dementia.